Heartflow (NASDAQ:HTFL) CEO John C.M. Farquhar Sells 22,562 Shares

Heartflow, Inc. (NASDAQ:HTFL) CEO John C.M. Farquhar sold 22,562 shares of the stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $28.50, for a total transaction of $643,017.00. Following the completion of the sale, the chief executive officer owned 496,835 shares of the company’s stock, valued at approximately $14,159,797.50. The trade was a 4.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John C.M. Farquhar also recently made the following trade(s):

• On Monday, May 11th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The shares were sold at an average price of $29.12, for a total transaction of $657,005.44.
• On Friday, April 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The shares were sold at an average price of $26.72, for a total transaction of $602,856.64.
• On Wednesday, March 18th, John C.M. Farquhar sold 9,725 shares of Heartflow stock. The shares were sold at an average price of $25.00, for a total transaction of $243,125.00.

Heartflow Trading Up 8.4%

Shares of HTFL stock traded up $2.57 during mid-day trading on Friday, reaching $33.24. The company’s stock had a trading volume of 1,889,853 shares, compared to its average volume of 1,165,800. Heartflow, Inc. has a 1-year low of $20.13 and a 1-year high of $41.22. The firm’s 50-day moving average is $29.30 and its two-hundred day moving average is $28.34.

Heartflow (NASDAQ:HTFL) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.08. The business had revenue of $52.59 million during the quarter. The firm’s revenue was up 41.3% on a year-over-year basis. On average, equities research analysts forecast that Heartflow, Inc. will post -0.82 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Heartflow

A number of hedge funds have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd acquired a new position in Heartflow during the 4th quarter valued at about $27,000. Russell Investments Group Ltd. acquired a new position in Heartflow during the 4th quarter valued at about $45,000. Essential Partners LLC acquired a new position in Heartflow during the 1st quarter valued at about $57,000. Legal & General Group Plc acquired a new position in Heartflow during the 3rd quarter valued at about $59,000. Finally, Strs Ohio acquired a new position in Heartflow during the 4th quarter valued at about $99,000.

Analyst Upgrades and Downgrades

HTFL has been the subject of a number of recent research reports. William Blair initiated coverage on shares of Heartflow in a research note on Monday, May 4th. They issued an “outperform” rating for the company. Piper Sandler restated an “overweight” rating on shares of Heartflow in a research note on Thursday. Canaccord Genuity Group lowered their target price on shares of Heartflow from $43.00 to $37.00 and set a “buy” rating on the stock in a report on Friday, May 15th. JPMorgan Chase & Co. lowered their target price on shares of Heartflow from $40.00 to $35.00 and set an “overweight” rating on the stock in a report on Thursday, March 19th. Finally, Wells Fargo & Company upped their target price on shares of Heartflow from $35.00 to $37.00 and gave the stock an “overweight” rating in a report on Friday, May 15th. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $37.00.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.